Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) and residual invasive disease at surgery, after chemotherapy and HER2-targeted neoadjuvant systemic therapy (NAST), have higher rates of recurrence and death than those attaining a pathological complete response1,2. Here, ERBB2 is linked to breast carcinoma.